# UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas

> **NCT00082017** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 20 (actual)

## Conditions studied

- Lymphoma, Large-Cell, Ki-1
- Lymphoma, T-Cell

## Interventions

- **DRUG:** UCN-01 (7-hydroxystaurosporine)

## Key facts

- **NCT ID:** NCT00082017
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-04-05
- **Primary completion:** 2011-09-27
- **Final completion:** 2011-09-27
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** IND was withdrawn by CTEP due to low accrual and cost of maintaining the IND.
- **Last updated:** 2017-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00082017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00082017, "UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00082017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*